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I.
As the decade ends, advocates and opponents of abortion rights
are demonstrating with heightened fervor. Lawyers continue to pre-
pare briefs for a lengthy docket of abortion cases, and elected offi-
cials dread having to vote on the matter. But there is reason to
believe that this seemingly intractable issue is approaching an uncer-
emonious solution.
The intensity of feelings will not suddenly disappear, but during
the next few years recognition will likely seep into the national con-
sciousness that the grounds for the debate have irrevocably changed.
The energy presently devoted to influencing political and legal insti-
tutions will ultimately subside in the face of a new technological real-
ity, the French abortion pill. This is said not to pass judgment on the
pill's propriety, nor on the positions of the protagonists on either
side of the abortion question. Like genetic engineering, nuclear
power, and automobiles, the pill is a technological development that
will comfort some and distress others, but all will feel its impact.
The abortion pill, named RU486, only recently began drawing
public attention, and many protagonists in the abortion debate have
not yet absorbed its public policy significance. The logic about
where the pill will lead is so compelling, however, that people are
bound increasingly to recognize the likelihood of its social conse-
quences. As they do, many will question whether the energy and
anxiety now so rampant will continue to have purpose.
II.
RU486 is a steroid that was synthesized by Dr. Etienne-Emile
Baulieu in 1980. Roussel-Uclaf, a French drug company, holds the
patent and has supplied the chemical to investigators around the
world. Clinical trials are underway in about 20 countries, including
France and China, where the drug is approved for use.
The pill is an antagonist of progesterone, a hormone that is nec-
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essary for the uterus to retain a fertilized egg. Progesterone serves
several functions during pregnancy, including conditioning the cell
lining of the uterus to accept embryo implantation, and suppressing
hormone action that triggers menstrual cycles. RU486 "fools" pro-
gesterone receptors on the cell lining and attaches to them in place
of the progesterone. In this way it blocks progesterone action. As a
result, the pill prevents implantation or retention of the embryo at
early stages of pregnancy, and the uterine lining breaks down. The
system dispels the fertilized egg along with the sloughed lining.
During the first nine weeks of pregnancy, a single dose of
RU486 followed a day or two later by a suppository containing pros-
taglandin, induces an abortion in nearly all cases. Prostaglandin is a
naturally occurring hormone that is also antagonistic to the action of
progesterone. Although the reliability of pill-induced abortions falls
after the tenth week, investigations with other chemicals and combi-
nations show promise into the second trimester. But, the present
technology alone could deal with most American abortions because
more than half occur during the first 8 weeks of pregnancy.
The pill's availability for widespread use in France did not come
easily. After finding the pill safe and effective in clinical trials during
the early 1980s, Dr. Baulieu campaigned to make it generally avail-
able. The Roussel company responded slowly, evidently concerned
about opposition from antiabortionists. After receiving encourage-
ment and approval from the French government, however, Roussel
announced that it would make the drug available in the fall of 1988.
In October of that year, the company suddenly announced it had sus-
pended plans to produce the pill because of public protests and boy-
cott threats. Coincidentally, the World Council of Gynecology and
Obstetrics was meeting in Rio De Janeiro at the time of the
announcement. The company's decision incensed many of the 9,500
physicians and medical experts in attendance. One group
announced it was preparing a list of Roussel's products that people
should boycott.'
The French government, which owns 36% of Roussel-Uclaf,
responded to the company's announcement by calling the drug "the
moral property of women," and ordered Roussel to reverse itself
I See Simons, A Medical Outcry Greets Suspension of Abortion Pill, N.Y. Times, Oct.
28, 1988, at 1, col. I.
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again.2 The company complied, and since November 1988, RU486
has been available to French physicians and hospitals.
The increasing number of women who choose pill abortions
rather than surgery is a good gauge of the drug's popularity. Injuly,
1989 the pill accounted for approximately 15% of French abortions,
but by October the proportion rose to about 30% and was still
climbing. According to Andre Ulmann, Roussel's medical director,
about 30,000 French women used the pill in the eleven months fol-
lowing its general availability.
3
The abortion pill induces bleeding comparable to a menstrual
period for about a week, and a few patients feel slight nausea and
cramps. Complications are rare, but the drug is best taken under a
physician's care because of the potential for heavy bleeding.
Although researchers and physicians have found the pill largely
effective and safe, there may be yet unknown long term health
effects, as recent studies suggest may be the case with contraceptive
pills. Several observers consider long term problems unlikely, how-
ever. Clinical tests with RU486 since 1982 have not revealed unto-
ward effects in the ensuing years and, unlike birth control pills that
must be taken on a regular basis, the abortion pill requires a single
administration. The drug metabolizes quickly; three-quarters is dis-
sipated within two days.
Beyond efficacy and safety lie other advantages. Unlike surgical
abortions, the pill eliminates the risk of injury or infection from phy-
sicians' instruments, as well as anesthesia complications. No tech-
nique could be easier, more private, or cheaper. An abortion pill
costs only a few dollars, a surgical abortion a few hundred dollars.
Under the French social security system, women have had to pay the
same amount, about $140, for chemically or surgically induced abor-
tions. The growing number of French women who choose the pill
therefore offers all the more testimony to its appeal. If patients had
to pay the cost differential for surgery, the rush to the pill doubtless
would be faster, but the simplicity and privacy of treatment by the
pill alone have been a strong incentive.
III.
The pharmaceutical companies' fear of the reaction from abor-
2 See Henry, Production of Abortion Pill Ordered, Baltimore Sun, Oct. 29, 1988, at 1,
col 1.
3 See Herman, The Politics of the Abortion Pill, Wash. Post Health, Oct. 3, 1989, at
12, col. 2.
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tion opponents has been the biggest obstacle to bringing RU486 to
the United States. Antiabortion groups have announced that they
will boycott any company that seeks to market the drug in this coun-
try. Indeed, shortly before the French government's 1988 endorse-
ment of RU486, David N. O'Steen, executive director of the National
Right to Life Committee in the United States, threatened such action
against the French company and its affiliates. In a letter to the
French Ambassador in Washington he wrote:
If Roussel-Uclaf or any other pharmaceutical company attempts to
manufacture or market RU486, National Right to Life would seri-
ously consider joining with other pro-life groups around the world
to initiate a boycott of the products of Roussel-Uclaf and firms affil-
iated with it through its parent company Hoechst in the Federal
Republic of Germany.
4
The French government ignored the threats, and to date there have
been no reported effects on Roussel-Uclaf sales.
Nevertheless, antiabortion groups continue to raise the boycott
specter. Dr. John Willke, who heads the National Right to Life Com-
mittee, says that any company marketing an abortion agent in the
United States "will be hit with an instant, massive, national boycott
of every product they [make], except those where there are no other
alternative drugs."5 In addition to concern about boycotts, drug
companies worry about product liability, especially in the birth con-
trol area. Legal defense and insurance costs involving the birth con-
trol pill have discouraged some from marketing oral contraceptives.
By the early 1980s, liability costs climbed higher in this area than for
other drug categories.
6
In any case, no company legally could market the abortion pill in
the United States during the next two or three years because the
Food and Drug Administration must approve the manufacture and
distribution of all new drugs, and its safety and effectiveness review
takes at least a few years. Moreover, the antiabortion White House
probably would not encourage an expedited review. Thus, despite
the promise of profits for the first company that brings the pill to the
United States, the effort faces obstacles and risks.
4 Letter from David N. O'Steen to His Excellency Emmanuel deMargerie,
Ambassador of France (June 21, 1988) (on file with the University of Pennsylvania Law
Review).
5 Chapman, The Politics of the Abortion Pill, Wash. Post Health, Oct. 3, 1989, at 13,
col. 2.
6 See Djerassi, The Bitter Pill, 245 SCIENCE 356, 357 (1989) (discussing a 1982
report by the Office of Technology Assessment).
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Yet it is hardly inconceivable that the government can keep the
pill out of this country. As RU486's popularity grows in France,
Roussel-Uclaf will manufacture more. In addition, other countries
including Great Britain and the Netherlands are moving closer to
permitting domestic distribution, and some stock is bound to appear
in the United States; all the sooner if the Supreme Court or state
governments substantially restrict abortion rights. If all American
abortion clinics closed and the federal and state governments
deemed the pill contraband, nothing could stop the tablets from get-
ting into this country. Many people believe that making RU486
available here would be an act of high moral purpose, whatever the
drug's legal status. Some have even coldly confided to me that if
abortion were illegal in the United States, they would not expect to
return empty handed from an overseas visit.
In making this observation I do not endorse unlawful activity,
but merely present a realistic scenario. People drank liquor when it
was illegal and smoke crack today. Even people in poor economic
circumstances will not be denied a substance they dearly want, as
cocaine and heroin addicts demonstrate daily. How much simpler
for a person to obtain a contraband tablet or two than an endless
supply of illegal narcotics.
The strength of commitment in the medical community to mar-
keting the abortion pill may be gleaned from the vigorous objections
raised by the thousands of physicians at the 1988 Rio conference,
when Roussel tried to suspend distribution plans. American abor-
tion rights leaders have suggested they will settle for nothing less
than the pill's availability here. Molly Yard, president of the National
Organization for Women, said her organization would meet with
drug company officials to encourage research and distribution. As
for keeping RU486 out of the United States, she said, "I know the
feminist community will not allow it." 7 As long as companies pro-
duce the pill in France or anywhere else, its ultimate accessibility
here is assured.
IV.
There is a precedent for the contentiousness related to the abor-
tion pill. A generation ago the legality of contraceptive devices
divided much of the nation. Then, as now, there were harsh debates.
In August 1966, a group of pickets carried signs in front of New York
7 Chapman, supra note 5, at 13, col. 2.
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City's St. Patrick's Cathedral claiming that "Rome fiddles as the
world yearns for birth control." Although the civil rights March on
Washington was held three years earlier, demonstrations for social
or political causes were not yet commonplace. A news report said
the contraception rights demonstration was "the first protest that
could be recalled taking place before the cathedral itself."8 In tak-
ing this action, contraception rights advocates conveyed their
extraordinary sense of purpose.
The opposition was no less determined. The American Roman
Catholic Bishops issued a statement that deplored "pressures for a
contraceptive way of life" and government activities that "seek
aggressively to persuade and even coerce the underprivileged to
practice birth control." 9 Meanwhile, the then recently created birth
control pill was becoming popular, and the new technology settled
the contraception argument as much as the government decision
did. A few years later, the birth control issue faded from the public
agenda.
Not all the mid-1960s conditions are analogous to today's.
Unlike the current executive branch which unambiguously opposes
abortions, the 1960s White House was not involved in the birth con-
trol debate. Moreover, the Supreme Court had just issued Griswold v.
Connecticut.'0 The Griswold Court held that states could not interfere
with a married couple's right to use birth control devices, and this
decision lent momentum to contraception rights efforts. No court
edict, however, could suddenly uproot an individual's moral ration-
ale for opposing birth control, a justification that arises from atti-
tudes, feelings, and values. Nevertheless, once the contraception pill
was available, its widespread use became matter of fact, and ques-
tions about whether or not it should be used became irrelevant. A
technological reality defused the controversy.
The intensity of conviction on both sides of the abortion ques-
tion is greater for many than it was with birth control, and a political
accommodation on abortion seems beyond reach. If the courts con-
tinue to protect abortion rights, opponents will remain angry. If
states restrict abortion, abortion rights advocates will chafe, but Roe
v. Wade1 1 created new conditions and new expectations.
The legal norm that has prevailed during the past 16 years has
8 N. Y. Times, Aug. 13, 1966, at 14, col. 2.
9 N. Y. Times, Nov. 15, 1966, at 25, coT. 1.
10 381 U.S. 479 (1965).
11 410 U.S. 113 (1973).
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strengthened the sense of legitimacy that abortion rights advocates
feel. The number of physicians, nurses, counselors, and others will-
ing to help facilitate abortions will be greater than before Roe,
whatever the government says; so will the number of women who
want an abortion and believe that having one is their right.
Any government attempt to revoke this perceived right will
leave battalions of citizens prepared to act in defiance. The early
pregnancy abortion pill can only make their efforts easier. In the
end, this new technology is likely to render early pregnancy abor-
tions as much a nonissue as birth control is today, and in the process
will have rescued the nation from a political nightmare.

